GlassScriptPhysician profile
Vikas K Patel
NPI 1235349598
$49,097.95
in general payments reported to CMS, 2019-2025
59 companies · $4,350 in 2025
The $4,350 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,336 · 2020: $4,141 · 2021: $1,723 · 2022: $8,574 · 2023: $13K · 2024: $11K · 2025: $4,350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $15K · Food and Beverage: $7,675 · Consulting Fee: $3,285 · Travel and Lodging: $2,419 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,850.00 |
| Food and Beverage | $7,675.38 |
| Consulting Fee | $3,285.00 |
| Travel and Lodging | $2,418.95 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $17,029.79 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $8,053.95 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Bard Peripheral Vascular, INC. | $6,430.05 | 2019-2023 | Venovo |
| Cardiovascular Systems INC. | $2,339.60 | 2019-2023 | Diamondback Coronary |
| Novartis Pharmaceuticals Corporation | $2,334.63 | 2019-2025 | |
| Abbott Laboratories | $1,952.21 | 2019-2025 | Optis, Pressurewire, Diamondback Peripheral |
| Boston Scientific Corporation | $1,896.81 | 2020-2025 | Watchman Flx, Avvigo Guidance System, Rotapro |
| Janssen Pharmaceuticals, INC | $981.75 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $694.56 | 2019-2025 | Eliquis, Camzyos |
| Medtronic Vascular, INC. | $680.75 | 2019-2020 | |
| Abiomed | $654.72 | 2019-2024 | Impella |
| Preventric Diagnostics, INC. | $539.82 | 2022 | |
| Pfizer INC. | $538.79 | 2019-2025 | |
| Amgen INC. | $437.39 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.43 | 2019-2024 | Jardiance |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $421.29 | 2022-2025 | Verquvo, Belsomra, Steglatro |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $391.59 | 2019-2023 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $367.87 | 2019-2025 | Farxiga, Wainua, Brilinta |
| W. L. Gore & Associates, INC. | $327.21 | 2019-2023 | Gore Cardioform Septal Occluder |
| Novo Nordisk INC | $204.69 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Heartflow, INC. | $190.91 | 2023 | Ffrct |
| Regeneron Healthcare Solutions, INC. | $163.60 | 2019-2024 | Evkeeza, Praluent |
| Terumo Medical Corporation | $147.16 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $146.26 | 2019-2023 | Onpattro |
| Penumbra, INC. | $144.81 | 2023 | Penumbra System |
| Esperion Therapeutics, INC. | $143.99 | 2021-2025 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $137.18 | 2019-2023 | Opsumit, Uptravi |
| Revance Therapeutics, INC. | $103.91 | 2025 | Daxxify |
| Teleflex LLC | $103.64 | 2019-2022 | |
| Edwards Lifesciences Corporation | $92.61 | 2019-2022 | |
| Chiesi USA, INC. | $82.79 | 2019-2021 | |
| Lantheus Medical Imaging, INC. | $71.65 | 2019-2022 | |
| Kerecis Limited | $66.16 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Cook Medical LLC | $64.70 | 2020-2024 | Icast Covered Stent System, 6mmx22mmx120cm |
| Sanofi-Aventis U.S. LLC | $64.66 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.76 | 2020-2022 | |
| Vifor Pharma, INC. | $49.94 | 2019 | |
| Amarin Pharma, INC. | $49.93 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $49.07 | 2024 | |
| Philips North America LLC | $47.56 | 2022-2023 | |
| Kiniksa Pharmaceuticals, LTD. | $45.04 | 2023 | Arcalyst |
| United Therapeutics Corporation | $35.05 | 2019-2025 | Tyvaso |
| Veryan Medical Incorporated | $24.84 | 2022 | |
| Avinger INC. | $24.71 | 2021 | |
| Cvrx, INC. | $24.34 | 2021 | |
| Surmodics, INC. | $23.88 | 2022 | |
| Daiichi Sankyo INC. | $23.70 | 2023 | Injectafer |
| Medicomp INC | $23.02 | 2025 | Telepatch Cardiac Monitor |
| Genentech USA, INC. | $22.19 | 2023 | Avastin, Tecentriq |
| Kiniksa Pharmaceuticals International, Plc | $20.74 | 2024 | Arcalyst |
| Biosense Webster, INC. | $20.57 | 2024 | Na |
| Ionis Pharmaceuticals, INC. | $19.86 | 2025 | Tryngolza |
| Infobionic, INC | $18.99 | 2020 | |
| Cardiva Medical, INC. | $18.17 | 2019 | |
| Imperative Care, INC | $17.50 | 2024 | Symphony Catheter |
| Csl Behring | $16.63 | 2019 | |
| Scpharmaceuticals INC. | $15.41 | 2023 | |
| Biotronik INC. | $13.45 | 2019 | |
| Lundbeck LLC | $12.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.